POINT Biopharma (PNT) - Analyst Ratings

POINT Biopharma (PNT) – Analyst Ratings

Dec 27, 2023 03:19 AM Fusion Pharmaceuticals (FUSN) is 'sole remaining clinical-stage, targeted radiopharm player,' seen as takeover target - Oppenheimer
Dec 21, 2023 04:30 AM Brookline Capital Markets Downgrades POINT Biopharma Global Inc. (PNT) to Hold
Oct 24, 2023 12:23 AM
Oct 5, 2023 04:36 PM
Oct 4, 2023 04:11 AM
Oct 4, 2023 02:44 AM
Oct 4, 2023 12:20 AM
Oct 3, 2023 12:25 PM
Jul 20, 2023 08:15 AM
Dec 14, 2022 05:14 PM
Dec 14, 2022 07:05 AM
Nov 30, 2022 06:04 AM
Oct 10, 2022 04:03 PM
Sep 15, 2022 04:10 PM
Sep 14, 2022 06:02 AM
Sep 6, 2022 04:33 PM
Sep 6, 2022 01:09 PM
Aug 16, 2022 06:22 AM
Jul 6, 2022 05:44 AM
Jun 17, 2022 06:42 AM
May 26, 2022 03:45 AM
Dec 1, 2021 03:23 AM
Jul 29, 2021 05:47 AM
Jul 27, 2021 07:43 AM
Jul 26, 2021 07:12 AM